Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis.

ABSTRACT:

Background

The majority of patients with coronavirus disease 2019 (COVID-19) have good prognoses, but some develop a critical illness that can lead to death. Evidence shows severe acute respiratory syndrome is closely related to the induced cytokine storm. Interleukin-6 is a key player; its role in systemic inflammation is well known.

Aim

To evaluate the effect of tocilizumab (TCZ), an interleukin-6 receptor antagonist, on the outcomes for patients with COVID-19 pneumonia.

Methods

PubMed, EMBASE, SCOPUS, Web of Science, MedRxiv, Science Direct, and the Cochrane Library were searched from inception to 9^th June 2020 for observational or prospective studies reporting results of hospitalized adult patients with COVID-19 infection treated with TCZ. Effect sizes

SUBMITTER: Petrelli F 

PROVIDER: S-EPMC8127418 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature